VYNE Therapeutics
VYNE
41 hedge funds and large institutions have $1.84M invested in VYNE Therapeutics in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 6 closing their positions.
0% more funds holding
Funds holding: 41 → 41 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0.01% less ownership
Funds ownership: 0.8% → 0.79% (-0.01%)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
43% less capital invested
Capital invested by funds: $3.25M → $1.84M (-$1.41M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$30.8K |
| 2 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$24.8K |
| 3 |
Jane Street
New York
|
+$18K |
| 4 |
Millennium Management
New York
|
+$12.2K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$8.87K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$53.7K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$50K |
| 3 |
Citigroup
New York
|
-$16K |
| 4 |
RC
RegentAtlantic Capital
Morristown,
New Jersey
|
-$10K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
LPL Financial
San Diego,
California
| $4K | – | – | – |
|
27
Mariner
Overland Park,
Kansas
| $3K | +$4.97K | +776 | New |
|
28
UBS Group
Zurich,
Switzerland
| $2K | -$6 | -1 | -0.2% |
|
29
Federated Hermes
Pittsburgh,
Pennsylvania
| $1K | – | – | – |
|
|
TSS
30
Two Sigma Securities
New York
| – | -$50K | -7,102 | Closed |
|
|
31
Citigroup
New York
| – | -$16K | -2,222 | Closed |
|
|
RC
32
RegentAtlantic Capital
Morristown,
New Jersey
| – | -$10K | -1,393 | Closed |
|
|
33
Ameriprise
Minneapolis,
Minnesota
| – | -$7K | -1,027 | Closed |
|
|
TFA
34
Tobias Financial Advisors
Plantation,
Florida
| – | -$4K | -611 | Closed |
|
|
CS
35
Credit Suisse
Zurich,
Switzerland
| – | -$1K | -136 | Closed |
|
36
Simplex Trading
Chicago,
Illinois
| – | -$26 | -4 | -80% |
|
|
HR
37
Howe & Rusling
Rochester,
New York
| – | +$13 | +2 | New |
|
38
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$224 | +35 | +3,500% |
|
|
AIM
39
Axiom Investment Management
New York
| – | +$359 | +56 | New |
|
40
Wells Fargo
San Francisco,
California
| – | +$371 | +58 | +69% |
|
VYNE Hedge Fund Activity: Q3 2022 in Review
41 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q3 2022, worth a combined $1.84M — down 43% from $3.25M a quarter earlier.
Fund positioning in VYNE was balanced in Q3 2022: 6 funds opened new positions, 6 closed out, 6 added to existing stakes and 8 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $30.8K. The largest seller was Vanguard Group, cutting an estimated $53.7K.
- 41 institutional investors held VYNE Therapeutics (VYNE) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $1.84M of VYNE Therapeutics stock for Q3 2022, down 43% quarter-over-quarter.
- 6 funds opened new VYNE Therapeutics positions in Q3 2022 and 6 closed out, a net change of 0 holders.
- The largest VYNE Therapeutics buyer in Q3 2022 was Citadel Advisors, an estimated $30.8K added.
- The largest VYNE Therapeutics seller in Q3 2022 was Vanguard Group, an estimated $53.7K sold.
Based on aggregated 13F filings for Q3 2022.